@article{521b761007d24c41bb3ba96c2231afcd,
title = "Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial)",
abstract = "This open-label, multicentre phase I/II study determined the maximum tolerated dose (MTD), safety and efficacy of clofarabine administered with cytarabine and idarubicin in newly diagnosed acute myeloid leukaemia (AML) patients lacking favourable genetic aberrations. The MTD was 30 mg/m2 clofarabine for patients below and above 60 years. The most frequently reported grade 3–4 non-haematological adverse events were infectious and gastrointestinal toxicities. Complete remission (CR)/CR with incomplete recovery rate was 67%. Allogeneic haematopoietic cell transplantation in first remission was feasible in a high proportion of younger AML patients and probably contributed to the favourable outcome compared to historical controls.",
keywords = "acute myeloid leukaemia, clofarabine, cytarabine, idarubicin, maximum tolerated dose",
author = "J{\"u}rgen Krauter and Walter Fiedler and Schlenk, {Richard F.} and Peter Paschka and Felicitas Thol and Michael L{\"u}bbert and Mohammed Wattad and Mareike Verbeek and Christian K{\"o}necke and Barbara Neuhaus and Armin Papkalla and Maxim Kebenko and Melanie Janning and Konstanze D{\"o}hner and Gaidzik, {Verena I.} and Heiko Becker and Christine Greil and Peter Reimer and G{\"o}tze, {Katharina S.} and Hartmut D{\"o}hner and Arnold Ganser and Michael Heuser",
note = "Publisher Copyright: {\textcopyright} 2018 British Society for Haematology and John Wiley & Sons Ltd",
year = "2018",
month = oct,
doi = "10.1111/bjh.15546",
language = "English",
volume = "183",
pages = "235--241",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley and Sons Inc.",
number = "2",
}